ADARx Pharmaceuticals (ADRX) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Zymeworks is the larger company by market cap ($1.90 billion vs $1.85 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | ZYME |
|---|---|---|
| Share price | $17.33 | $26.53 |
| Market cap | $1.85B | $1.90B |
| 1-day change | -6.73% | +3.43% |
| YTD return | — | +0.76% |
| 1-year return | — | +60.79% |
| 5-year return | — | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-1.16 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $31.34 |
| 52-week low | $17.20 | $16.00 |
| Distance from 52-week high | -25.33% | -15.35% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +55.33% |
| Average volume | 1.42M | 676.63K |
| Shares outstanding | 106.80M | 71.20M |
| Employees | 100 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
ADRX vs ZYME FAQ
Which is bigger, ADARx Pharmaceuticals or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.90B compared with $1.85B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.